February Newsletter
https://conta.cc/4gsbQNM
OLUMIANT® Receives Health Canada Approval, Becoming the Second Approved Treatment for Severe Alopecia Areata in Canada
Eli Lilly Canada Inc. announced today that OLUMIANT (baricitinib) received regulatory approval for its severe alopecia areata indication via Notice of Compliance (NOC) from Health Canada.
Navigate With Confidence
Navigate with Confidence: Mental Health Resources Resources Music & Wellbeing Handbook
LITFULO™ Receives Health Canada Approval, Becoming the First Approved Treatment for Severe Alopecia Areata in Canada
This press release was posted on Pfizer's website on December 4, 2023. A dual JAK3/TEC inhibitor, LITFULO™ (ritlecitinib) is approved